Malaria chemotherapy: recent advances in drug development.
Malaria is a disease caused by parasitic protozoa of the genus Plasmodium. Despite significant advances in understanding the disease and the parasite biology, malaria still remains one of the leading causes of morbidity and mortality, particularly in malaria-endemic regions of the world. The main factor hampering malaria control is the high degree of resistance developed by Plasmodium species against several classes of drugs. Artemisinin-based Combination Therapy (ACT) is the most rapidly acting antimalarial treatment effective against multi-drug resistant strains, and is, at present, the only group of antimalarial drugs to which resistance by Plasmodium falciparum has not developed yet in the field, even though the isolation of artemisinin-resistant strains is raising concern. As a result, discovering and developing novel antimalarial agents is one of the greatest challenges facing malaria control today. This review covers patent literature from 2007 to date regarding small molecules or natural compounds targeting the asexual forms of the parasite. Recent patents filed and issued for ameliorating conventional antimalarial treatment methods by non-conventional dosage forms are also reviewed.
Gemma
Sandra
S
Department of Pharmaceutical and Applied Chemistry, University of Siena, via Aldo Moro 2, 53100 Siena, Italy.
Travagli
Valter
V
Savini
Luisa
L
Novellino
Ettore
E
Campiani
Giuseppe
G
Butini
Stefania
S
D000818:Animals; D000962:Antimalarials / Q000737:chemistry* / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D018432:Drug Resistance, Multiple / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000235:genetics / Q000469:parasitology; D010330:Patents as Topic / Q000331:legislation & jurisprudence; D010963:Plasmodium falciparum / Q000187:drug effects / Q000502:physiology
D000962:Antimalarials